Cardiac hypertrophy is accompanied by maladaptive cardiac remodeling, which leads to heart failure or sudden death. MicroRNAs (miRNAs) are a class of small, noncoding RNAs that mediate posttranscriptional gene silencing. Recent studies show that miRNAs are involved in the pathogenesis of hypertrophy, but their signaling regulations remain to be understood. Here, we report that miR-23a is a pro-hypertrophic miRNA, and its expression is regulated by the transcription factor, nuclear factor of activated T cells (NFATc3). The results showed that miR-23a expression was up-regulated upon treatment with the hypertrophic stimuli including isoproterenol and aldosterone. Knockdown of miR-23a could attenuate hypertrophy, suggesting that miR-23a is able to convey the hypertrophic signal. In exploring the molecular mechanism by which miR-23a is up-regulated, we identified that NFATc3 could directly activate miR-23a expression through the transcriptional machinery. The muscle specific ring finger protein 1, an anti-hypertrophic protein, was identified to be a target of miR-23a. Its translation could be suppressed by miR-23a. Our data provide a model in which the miRNA expression is regulated by the hypertrophic transcriptional factor.
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calcineurin ͉ microRNA ͉ MuRF1 C ardiac hypertrophy is an early milestone of many heart diseases (1, 2), which is associated with changes in gene expression (3) . MicroRNAs (miRNAs) are small noncoding RNA molecules that regulate pathophysiological processes such as cell differentiation, apoptosis, cell proliferation, and organ development (4, 5) . Recently, the work on miRNAs renovates our understanding about the regulation of cardiac hypertrophy (6, 7) . Functional studies reveal that different miRNAs have distinct effects on cardiac hypertrophy. For example, inhibition of miR-133 causes significant cardiac hypertrophy (8) . In contrast, miR-208 is required for cardiomyocyte hypertrophy in response to stress and hypothyroidism (9). Overexpression of miR-195 in mice hearts results in severe cardiac hypertrophy (10). Overexpression of miR-214, miR-24, or miR-23a in the cardiomyocytes also causes significant hypertrophy (10). Thus, it appears that miRNAs play multiple and essential roles in the regulation of cardiac hypertrophy.
The levels of many miRNAs have been demonstrated to be altered in cardiac hypertrophy by a series of high-throughput miRNA microarray analysis (10-12). Nevertheless, the signaling pathways that regulate the expression of miRNAs during cardiac hypertrophy remain largely unknown. It is reported that serum response factor (SRF) can directly bind to the promoter of miR-1-1 and miR-1-2 genes and activate their expression (13) . Nuclear factor of activated T cells (NFAT) is a transcription factor. Currently, 5 isoforms of NFAT have been identified (14) of which NFATc3 is well-documented to play a key role in mediating the hypertrophic signal of calcineurin as well as other stimuli (15) . It is not yet clear whether NFATc3 can regulate cardiac hypertrophy through targeting miRNAs.
The muscle specific ring finger protein 1 (MuRF1) is an antihypertrophic factor. MuRF1 knockout mice demonstrate exaggerated cardiac hypertrophy in response to pressure overload (16) . It remains unknown whether MuRF1 is a target of miRNAs in the hypertrophic cascades.
The present work aimed at elucidating whether miRNAs are involved in the hypertrophic pathway regulated by NAFTc3. Our results show that miR-23a is a downstream mediator of NFATc3 in induction of hypertrophy. NFATc3 can directly bind to the promoter region of miR-23a and activate its expression. Consequently, miR-23a may convey the hypertrophic signal by suppressing the translation of MuRF1. These results reveal a model to understanding the molecular regulation of miRNAs in cardiac hypertrophy. (17) (18) (19) (20) . We attempted to understand whether miRNAs participate in conveying their hypertrophic signals. As shown in Fig. 1 A and B , Iso-or Aldo-treated cells displayed an increase in cell surface area. We analyzed the expression levels of miR-23a, miR-27a, and miR-24, which are located in the miR23aϷ27aϷ24-2 cluster. Their expression levels were significantly up-regulated upon treatment with Iso (Fig. 1C) or Aldo (Fig. 1D) .
The elevations of these miRNAs led us to consider whether they all are essential for mediating the hypertrophic effect of Iso or Aldo. To this end, the antagomirs of miR-23a, miR-24, and miR-27a were used to knockdown their expression, respectively. miR-23a knockdown could attenuate Iso-induced hypertrophic responses assessed by the visualization of sarcomere organization (Fig. 1E) , cell surface area measurement (Fig. 1F) , assessment of the hypertrophic markers including atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and ␤-myosin heavy chain (␤-MHC) (Fig. 1G) , and the protein/DNA ratio analysis (Fig. 1H) . A similar result was obtained from the hypertrophic model of Aldo (Fig. S1  A, B, C) . Surprisingly, knockdown of miR-24 or miR-27a resulted in no significant alterations in the hypertrophic responses induced by Iso or Aldo (Fig. S1D) . We detected whether the administration of the antagomirs indeed could inf luence the levels of miR23a, miR-27a, and miR-24. The levels of miR-23a were decreased by the administration of miR-23a antagomirs (Fig. 1I) , which was also the case for miR-27a and miR-24 (Fig. S1E) . These results indicate that miR-23a is involved in mediating the hypertrophic effects of Iso and Aldo. Calcineurin is a mediator of Iso-or Aldo-induced hypertrophy (18, 21) . To understand the relationship between calcineurin and miR23a in the hypertrophic cascades of Iso and Aldo, we tested whether calcineurin is able to influence miR-23a levels. Enforced expression of the constitutively active calcineurin could significantly increase the levels of miR-23a ( Fig. 2A) . Calcineurin inhibitors including cyclosporin and FK506 were able to attenuate miR-23a elevation induced by Iso. Furthermore, cain, a specific endogenous suppressor of calcineurin (22) , could suppress the expression of miR-23a (Fig. 2B) . Cain also inhibited Aldo-induced up-regulation of miR23a (Fig. S2 A) . These data suggest that Iso-and Aldo-induced miR-23a up-regulation depends on calcineurin. (23, 24) . Calcineurin-dependent miR-23a up-regulation encouraged us to explore the relationship between NFATc3 and miR-23a in the hypertrophic cascades of Iso and Aldo. To this end, NFATc3 RNAi was produced, and it could decrease the expression levels of total NFATc3 and the phosphorylated NFATc3 (Fig. 2C) . Knockdown of NFATc3 inhibited the hypertrophic responses (Fig. 2D ) and the expression of miR-23a (Fig. 2E) upon treatment with Iso. Knockdown of NFATc3 also could lead to a reduction in the hypertrophic response and the levels of miR-23a upon treatment with Aldo ( Fig.   S2 B and C) . These data demonstrate that NFATc3 controls the expression of miR-23a during cardiomyocyte hypertrophy induced by Iso or Aldo.
NFATc3 Is a Downstream Mediator of Calcineurin in Hypertrophy
To further confirm whether miR-23a is a downstream target of calcineurin-NFATc3 pathway, we tested whether calcineurin regulates miR-23a through NFATc3. The constitutively active calcineurin (caCN) could lead to hypertrophy (Fig. 2F) as well as an elevation of miR-23a (Fig. 2G ) in the absence but not presence of NFATc3-RNAi. Taken together, it appears that NFATc3 is required for calcineurin to regulate miR-23a levels. promoter sequence of the miR-23aϷ27aϷ24-2 cluster between human and rat using rvista (http://rvista.dcode.org). We observed that there is 1 optimal and conservative NFAT binding site in the promoter region of the miR-23aϷ27aϷ24-2 cluster (Fig. 3A ). Second, we tested whether NFATc3 could directly bind to the promoter region. An association of NFATc3 with the promoter of miR-23aϷ27aϷ24-2 could be observed (Fig. 3B ). Third, we tested whether NFATc3 can influence the promoter activity of miR23aϷ27aϷ24-2. A fragment from [minsu]799 to Ϫ1 of the rat premiR-23a was produced and fused to a luciferase reporter gene. The transcriptional activity of the miR-23aϷ27aϷ24-2 promoter was significantly increased in the presence of the constitutively active NFATc3 (⌬NFATc3). Mutations in the NFAT binding site of the promoter abolished its response to ⌬NFATc3 (Fig. 3C ). Finally, we tested whether endogenous NFATc3 is able to influence the promoter activity of miR-23aϷ27aϷ24-2. The promoter of miR-23aϷ27aϷ24-2 was activated upon Iso (Fig. 3D) or Aldo (Fig.  3E ) treatment, but its activation was abolished when NFATc3 was knocked down by RNAi. Taken together, these data suggest that miR-23a is a direct transcriptional target of NFATc3.
miR-23a Is Able to Convey the Hypertrophic Signal of Calcineurin and
NAFT. We tested whether miR-23a participates in mediating the hypertrophic signal of calcineurin and NFATc3. miR-23a antagomir could abolish the constitutively active calcineurin-and NFATc3-induced cardiomyocyte hypertrophy as revealed by sarcomere organization (Fig. 4A) , cells surface and the hypertrophic marker measurement (Fig. 4B) , and protein/DNA ratio analysis (Fig. 4C) . Administration of miR-23a antagomir led to a reduction in miR-23a levels (Fig. 4D ). These results demonstrate that miR23a is a component of calcineurin-NFATc3 hypertrophic pathway.
MuRF1 Is a Target of miR-23a. To find out the molecular target of miR-23a, we searched the potential targets of miR-23a using the program of target scan (http://www.targetscan.org/). MuRF1 has a conservative miR-23a 'seed' sequence in its 3ЈUTR (Fig. 5A ).
MuRF1 is an anti-hypertrophic molecule (16, 27) , and MuRF1 knockout mice demonstrate exaggerated cardiac hypertrophy in response to pressure overload (16) . These lines of evidence encouraged us to test whether MuRF1 is a downstream target of miR-23a in the hypertrophic pathway. We detected the expression levels of MuRF1 in the hypertrophic model of Iso and Aldo. MuRF1 protein levels were decreased upon treatment with Iso or Aldo (Fig. 5B) . Subsequently, we analyzed the effect of miR-23a on MuRF1 translation. miR-23a could significantly decrease the luciferase activity of MuRF1-3ЈUTR. miR-23a antagomir was able to rescue MuRF1-3ЈUTR luciferase activity (Fig. 5C ). To understand whether miR-23a indeed can influence the protein translation of MuRF1, we analyzed the protein levels of MuRF1 in cells cotransfected with the constructs of miR-23a and MuRF1-3ЈUTR. MuRF1 expression could be suppressed by miR-23a in a dosedependent manner (Fig. 5D) . We then overexpressed miR-23a in the cardiomyocytes to test if endogenous MuRF1 is regulated by miR-23a. MuRF1 protein but not mRNA levels were significantly decreased in the presence of miR-23a (Fig. 5E ), suggesting that miR-23a predominantly suppresses MuRF1 translation. To definitively test whether miR-23a targets MuRF1, we used target protector technology (28) . Administration of MuRF1 target protector against miR-23a could attenuate the reduction in MuRF1 levels as well as hypertrophic responses induced by miR-23a (Fig. 5F ). These data suggest that MuRF1 is a target of miR-23a. To understand whether MuRF1 plays a functional role in hypertrophic cascades of Iso or Aldo, we tested whether enforced expression of MuRF1 can influence hypertrophy induced by these stimuli. We constructed adenovirus harboring MuRF1 which only contains the protein coding sequence. As shown in Fig. 5G , miR-23a was unable to influence the expression of MuRF1 without 3ЈUTR. Enforced expression of miR-23a resulted in cardiomyocyte hypertrophy that was attenuated by MuRF1 (Fig. 5H) . MuRF1 also was able to inhibit hypertrophy induced by Iso or Aldo (Fig. 5I) . These data suggest that miR-23a and MuRF1 are both involved in the regulation of hypertrophy.
To further confirm the involvement of MuRF1 in hypertrophy, we analyzed the protein and ubiquitination levels of troponin I, which has been shown to be degraded by ubiquitin system through MuRF1-dependent manner (29) . As shown in Fig. S3 , Iso treatment resulted in an elevation in troponin I protein levels (upper panel), and a reduction in troponin I ubiquitination levels (lower panel), that could be attenuated by enforced expression of MuRF1. Thus, it appears that troponin I, a downstream target of MuRF1, is altered in the hypertrophic model of Iso.
miR-23a Is Necessary for the Induction of Hypertrophy In
Vivo. Finally, we tested whether miR-23a is necessary for Iso to induce hypertrophy in the animal model. The expression levels of miR-23a were up-regulated in hearts upon Iso treatment (Fig. 6A) . To understand the functional role of miR-23a in vivo, we used its antagomir to test if knockdown of miR-23a can influence the effect of Iso on cardiac hypertrophy. miRNA silence through infusion with minipumps requires the amount of antagomir at the milligram level (8) . We tried antagomir at 5 (Fig. S4A) , 12.5 (Fig. S4B) , or 25 mg/kg/d, and observed that 25 mg/kg/d could effectively reduce miR-23a levels (Fig. 6B) . The antagomir could be delivered to the heart as revealed by fluorescent analysis (Fig. S4C) . To further understand the delivery of the antagomir, we detected its distribution and effect in the liver because the liver expresses miR-23a under physiological conditions (30) . The antagomir could be observed in the liver (Fig.  S5A) . Concomitantly, the miR-23a levels were reduced in the liver (Fig. S5B) . However, the serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) activities were not significantly altered (Fig. S5C) . miR-23a antagomir inhibited Iso-induced hypertrophy revealed by heart weight/body weight ratio (Fig. 6C) , hypertrophic phenotype and cross-sectional areas (Fig. 6D) , the expression levels of hypertrophic markers including ANP, BNP, and ␤-MHC (Fig. 6E) , as well as cardiac size and function (Table S1 ). Finally, we observed that suppression of miR-23a by its antagomir restored the expression of MuRF1 (Fig. 6F) . These data suggest that miR-23a is required for Iso to induce cardiac hypertrophy in vivo.
Role of miR-23a in Alternative Hypertrophic Pathway of Iso. Our above results reveal that miR-23a can be a downstream mediator of calcineurin and NFATc3 in conveying the hypertrophic signal, and MuRF1 is a target of miR-23a. We asked whether miR-23a plays a role in other hypertrophic pathways in the Iso model. Protein kinase A (PKA) transgenic mice demonstrate cardiac hypertrophy (31) . However, inhibition of PKA does not attenuate hypertrophic responses upon treatment with Iso at a low dose (32) . These studies suggest that PKA activation is conditional in the hypertrophic model of Iso. To understand the involvement of PKA in our experimental conditions, we tested whether inhibition of PKA can influence hypertrophy. Administration of H89, a PKA inhibitor, slightly attenuated hypertrophy induced by Iso at 10 M, but significantly inhibited hypertrophy induced by Iso at 30 M (Fig.  S6A) . These results suggest that PKA pathway is significantly activated when Iso is at a high dose. Knockdown of miR-23a (Fig.  S6B) or NFATc3 (Fig. S6C) , inhibition of calcineurin by cain (Fig.  S6D) , or enforced expression of MuRF1 (Fig. S6E ) could partially attenuate hypertrophic responses upon treatment with 30 M Iso. These data suggest that miR-23a is not the predominant mediator of PKA pathway.
Discussion miRNAs remain at a constant level under physiological conditions. However, their levels are altered in response to the pathological insults, thereby leading to the pathogenesis of heart diseases. A key question as to how the expression of miRNAs is regulated in cardiac hypertrophy remains to be answered. The calcineurin-NFATc3 pathway plays an important role in conveying the signals for a variety of hypertrophic stimuli (14, 33, 34) . Our present study reveals that miR-23a can mediate the hypertrophic signals. Furthermore, miR-23a is transcriptionally regulated by NFATc3. In addition, MuRF1 is a target of miR-23a in inducing hypertrophy. Taken together, our data provide evidence indicating that the miRNA expression is regulated by the hypertrophic transcription factor, NFATc3. miRNAs levels are altered in response to hypertrophic stimulation (10, 12). Our present work shows that miR-23a is up-regulated by hypertrophic stimuli. Knockdown of miR-23a is crucial for the formation of cardiomyocyte hypertrophy upon treatment with Iso and Aldo. miR-23a has been found to be up-regulated during cardiac hypertrophy induced by pressure overload, and overexpression of miR-23a is able to initiate hypertrophic responses (10). Thus, it appears that miR-23a indeed is a pro-hypertrophic miRNA, and it widely participates in the regulation of cardiac hypertrophy.
miR-23a, miR-24, and miR-27a are in the same cluster, but the up-regulation of miR-27a and miR-24 occurred later than that of miR-23a (Fig. 1) . One explanation for such diversity is that miR-23a is closest to the binding site of NFATc3. Another is that because there are more than 70 nucleotides between miR-23a and miR-24 as well as miR-27a in the rat genome, we cannot exclude the possibility that miR-24 and/or miR-27a are also under the control of other known or unknown transcriptional factors. Surprisingly, miR-23a but not miR-27a and miR-24 is necessary for cardiomyocyte hypertrophy upon treatment with Iso and Aldo. Thus, it is apparent that miR-23a already initiates the hypertrophic program, whereas miR-27a and miR-24 cannot exert a synergistic effect. A dozen of miRNAs including miR-27a and miR-24 have been shown to be up-regulated in heart upon pressure overload (10). Future studies are required to specifically elucidate the role of miR-27a and miR-24 in initiating a hypertrophic program.
To further investigate the function of miR-23a, we searched its targets and found that MuRF1 is its downstream target. MuRF1 is a crucial anti-hypertrophic factor (16, 29, 35) . It appears that different miRNAs have distinct mechanisms in regulating hypertrophy. For example, miR-133 inhibits hypertrophy through targeting RhoA and Cdc42 (8) . miR-208 initiates cardiomyocyte hypertrophy by regulating triiodothyronine-dependent repression of ␤-MHC (9). A miRNA may have multiple targets. To understand if miR-23a can influence the mRNA levels of other genes, we performed the transcriptome microarray and found that the expression levels of a variety of genes are altered upon stimulation with miR-23a (Fig. S7) . For example, miR-23a can stimulate early growth response 1 (Egr-1) expression, whereas the latter has been shown to be up-regulated in cardiac hypertrophy (36, 37) . Pituitary tumor-transforming gene-1 (Pttg1), a molecule in the hypertrophic cascades (38) , can be up-regulated by miR-23a. It would be interesting to study how miR-23a directly and indirectly targets these molecules. In addition, we analyzed the potential targets of miR-23a using http://www.targetscan.org. Those factors that may be potentially related to cardiac hypertrophy are listed in Table S2 .
Enforced expression of MuRF1 alone does not significantly induce cardiomyocyte atrophy (35) . Our present study obtained a similar result. It could be possible that MuRF1 alone is unable to induce cardiomyocyte atrophy, or it may hold true under different conditions.
To understand the expression levels of other microRNAs in response to the treatment with Iso, we performed miRNA microarray analysis. miR-23a levels were up-regulated. However, miR-24 and miR-27a elevation could not be observed, although our data obtained from qRT-PCR in Fig. 1C shows their elevation. One explanation for such a discrepancy can be the sensitivity of qRT-PCR is higher than that of microarray. A variety of other miRNAs was up-or down-regulated (Fig. S8) . Their roles in the hypertrophic program of Iso will be investigated in future studies.
Cardiac hypertrophy induced by Iso and Aldo can be controlled by complex molecular mechanisms or signaling pathways. Although the present work shows that miR-23a can be regulated by calcineurin and NFATc3, our results do not exclude the involvements of any other molecules and/or pathways that can regulate miR-23a directly or indirectly dependent on calcineurin and NFATc3. Other calcineurin-and NFATc3-independent pathways in the hypertrophic model of Iso and Aldo as well as their roles in regulating miR-23a remain to be further identified.
In conclusion, our present study demonstrates that miR-23a is transcriptionally regulated by NFATc3. miR-23a can mediate the hypertrophic signal of NFAFc3 as well as its upstream regulator, calcineurin. Furthermore, miR-23a conveys the hypertrophic signal by targeting the anti-hypertrophic protein, MuRF1. Our results may provide important information for further studies to explore the beneficial effect of targeting miRNAs as a biological means for the treatment of maladaptive hypertrophy as well as heart failure.
Materials and Methods
Cardiomyocyte Culture, Cell Surface Area Measurement, and Protein/DNA Ratio Analysis. Neonatal rat cardiomyocytes were isolated from 1-to 2-day-old Wistar rats. Details are in SI Materials and Methods.
Quantitative Reverse Transcription-PCR (qRT-PCR).
Stem-loop qRT-PCR for mature miRNAs was performed on an Applied Biosystems AB 7000 Real Time PCR system. Total RNA was extracted using TRIzol reagent. RNA was reverse transcribed with reverse transcriptase (ReverTra Ace, Toyobo). Details are in SI Materials and Methods.
Chromatin Immunoprecipitation (ChIP). The purified DNA was used as template and amplified with the following primer sets: 5Ј-TTGAGCCACCAGGTGCAACTGT-3Ј; 5Ј-GAAAGCCCGAGTAAGCCGAGT-3Ј. Details are in SI Materials and Methods. miR-23a Silencing. Chemically modified antagomir complementary to miR-23a were used to inhibit its expression. The antagomir sequence is 5Ј-GGAAAUC-CCUGGCAAUGUGAU-3Ј. Chemically modified oligonucleotides 5Ј-CAGUACU-UUUGUGUAGUACAA-3Ј were used as a negative control (antagomir-NC). All of the bases were 2Ј-OMe modified. Antagomir oligonucleotides were synthesized and purified with high-performance liquid chromatography by GenePharma Co. Ltd. Cells were transfected with antagomir or antagomir-NC using Lipofectamin 2000 (Invitrogen). 
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